Program
Alpha V Beta 8 Antagonist PF-06940434
In Pfizer’s pipeline, Integrin alpha-V/beta-8 antagonist
. Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Pfizer.
Furthest: phase 1, since Oct 30, 20191 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 10 open or running | phase 1since Oct 30, 2019 | Oct 30, 2019 | none ahead |
- Named in Pfizer’s own pipeline as
PF-06940434
, phase 1, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2019First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04152018 · 85 enrolled · United States, Australia, Korea, Republic of and more
TargetBeta
“Integrin alpha-V/beta-8 antagonist”the company's pipeline, read by Claude · source
“An antagonist of integrin alpha v beta 8, with potential antineoplastic activity. Upon administration, PF-06940434 selectively binds to and blocks the receptor for integrin alpha v beta 8, thereby preventing integrin alpha v beta 8 binding. This may result in the inhibition of cell adhesion in th…”NCIt, read by Claude
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04152018Squamous Cell Carcinoma of Head and Neck · United States, Australia, Korea, Republic of and more | 1 | Terminated | Dec 10, 2024 | 85 |
How it is read
Names in the registry
- “PF-06940434”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.